Priority review vouchers: A winning example of government intervention spurring innovation for rare pediatric diseases
10 years and a billion dollars. These are commonly cited statistics for the time and investment required to bring a new pharmaceutical drug or biologic to market. With this staggering cost profile, pharmaceutical companies look for opportunities with the largest product sales potential. This often leads them to prioritize investments in therapeutics for diseases with […]